MCID: ATY042
MIFTS: 50

Atypical Chronic Myeloid Leukemia

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 12 59 15
Subacute Myeloid Leukemia 12 59 15
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 44 73
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Granulocytic Leukemia 12
Subacute Myelogenous Leukemia 12
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

59
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060597 DOID:8747
ICD10 33 C92.2
MeSH 44 D054438
NCIt 50 C3519
SNOMED-CT 68 95278004
Orphanet 59 ORPHA98824
MESH via Orphanet 45 D054438
UMLS via Orphanet 74 C1292772 C0349640
ICD10 via Orphanet 34 C92.2

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as subacute myeloid leukemia, is related to myeloid leukemia and leukemia. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Cytarabine and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder belonging... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 myeloid leukemia 29.3 ABL1 CSF3R JAK2 RUNX1
2 leukemia 29.2 ABL1 CSF3R JAK2 RUNX1
3 chronic neutrophilic leukemia 29.0 ASXL1 CSF3R SETBP1
4 myeloproliferative neoplasm 28.6 ABL1 FGFR1 JAK2 PDGFRA
5 chronic myelomonocytic leukemia 28.3 ASXL1 JAK2 RUNX1 SETBP1
6 leukemia, chronic myeloid 28.2 ABL1 CSF3R FGFR1 JAK2 PDGFRA RUNX1
7 myelodysplastic myeloproliferative cancer 28.0 ASXL1 CSF3R JAK2 SETBP1
8 leukemia, acute myeloid 26.1 ABL1 ASXL1 CSF3R JAK2 RUNX1 SETBP1
9 primary hypereosinophilic syndrome 10.2 FGFR1 PDGFRA
10 splenomegaly 10.2 JAK2 SETBP1
11 pdgfrb-associated chronic eosinophilic leukemia 10.2
12 neutrophilia, hereditary 10.0 CSF3R JAK2
13 refractory anemia with excess blasts 9.9 ASXL1 SETBP1
14 chronic eosinophilic leukemia 9.8 ABL1 FGFR1 PDGFRA
15 sm-ahnmd 9.8 ASXL1 PDGFRA
16 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.8 FGFR1 JAK2 PDGFRA
17 thrombocytopenia-absent radius syndrome 9.8 FGFR1 JAK2
18 polycythemia vera 9.8 ABL1 JAK2 PDGFRA
19 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
20 tetrasomy 21 9.8
21 leukocyte disease 9.8 CSF3R PDGFRA
22 core binding factor acute myeloid leukemia 9.7 JAK2 RUNX1
23 hypereosinophilic syndrome 9.7 ABL1 FGFR1 PDGFRA
24 systemic mastocytosis 9.7 FGFR1 JAK2 PDGFRA
25 lymphoblastic leukemia, acute, with lymphomatous features 9.7 ABL1 FGFR1 JAK2
26 8p11 myeloproliferative syndrome 9.7 FGFR1 RUNX1
27 leukemia, acute lymphoblastic 3 9.7 ABL1 PDGFRA RUNX1
28 budd-chiari syndrome 9.6 JAK2 PDGFRA
29 severe congenital neutropenia 9.4 CSF3R JAK2 RUNX1
30 lymphoblastic leukemia 9.4 ABL1 JAK2 RUNX1
31 juvenile myelomonocytic leukemia 9.2 JAK2 PDGFRA RUNX1 SETBP1
32 essential thrombocythemia 9.2 ABL1 ASXL1 JAK2
33 refractory anemia 9.1 ASXL1 JAK2 RUNX1
34 hematologic cancer 8.4 ABL1 CSF3R FGFR1 JAK2 RUNX1
35 bone marrow cancer 8.0 ABL1 CSF3R FGFR1 JAK2 PDGFRA RUNX1
36 myelodysplastic syndrome 7.6 ABL1 ASXL1 CSF3R JAK2 RUNX1 SETBP1

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 CSF3R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.72 SETBP1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 CSF3R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.72 PDGFRA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.72 CSF3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.72 CSF3R PDGFRA SETBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.72 SETBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.72 SETBP1 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 SETBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 SETBP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 SETBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.72 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.72 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 PDGFRA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 PDGFRA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 PDGFRA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.72 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 PDGFRA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.72 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 SETBP1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 ABL1 PDGFRA ASXL1 RUNX1 CSF3R FGFR1
2 endocrine/exocrine gland MP:0005379 9.87 ASXL1 RUNX1 CSF3R FGFR1 JAK2 ABL1
3 hematopoietic system MP:0005397 9.8 ABL1 PDGFRA ASXL1 RUNX1 CSF3R FGFR1
4 immune system MP:0005387 9.7 ABL1 PDGFRA ASXL1 RUNX1 CSF3R FGFR1
5 mortality/aging MP:0010768 9.56 ASXL1 RUNX1 SETBP1 CSF3R FGFR1 JAK2
6 skeleton MP:0005390 9.1 ABL1 PDGFRA ASXL1 RUNX1 FGFR1 JAK2

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
2
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
8
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
9
Azacitidine Approved, Investigational Phase 3,Phase 1 320-67-2 9444
10
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
13
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
14
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
15
Acyclovir Approved Phase 3 59277-89-3 2022
16
Ephedrine Approved Phase 3 299-42-3 9294
17
Pseudoephedrine Approved Phase 3 90-82-4 7028
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Daunorubicin Approved Phase 3 20830-81-3 30323
20
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
21
Thioguanine Approved Phase 3 154-42-7 2723601
22
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
23
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
24
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
25
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
26 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
27
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
28
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
29
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
30
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
31
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
32
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
33 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
34 6-Mercaptopurine Phase 3
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
38 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
48 Interferon-alpha Phase 3,Phase 2
49 interferons Phase 3,Phase 2
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
7 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
8 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
9 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
16 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
25 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
26 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
27 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
28 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
29 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
30 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
31 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
32 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
33 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
35 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
36 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
37 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
38 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
39 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
40 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
41 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
42 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
43 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
46 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
47 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
48 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
50 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow, Neutrophil, Breast, Liver, T Cells

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show all 47)
# Title Authors Year
1
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
2
A typical atypical chronic myeloid leukemia. ( 29744086 )
2018
3
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. ( 29455651 )
2018
4
Atypical chronic myeloid leukemia: a rare entity with management challenges. ( 29226717 )
2018
5
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. ( 29227326 )
2017
6
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. ( 28314085 )
2017
7
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
8
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. ( 28927137 )
2017
9
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. ( 29025591 )
2017
10
Atypical chronic myeloid leukemia in a German Shepherd Dog. ( 28205462 )
2017
11
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. ( 27853001 )
2016
12
Activity of single-agent decitabine in atypical chronic myeloid leukemia. ( 26378157 )
2016
13
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. ( 26870268 )
2016
14
How I treat atypical chronic myeloid leukemia. ( 27899359 )
2016
15
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. ( 28666496 )
2016
16
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. ( 26274939 )
2016
17
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
18
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. ( 25426665 )
2015
19
Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor A9 rearrangement. ( 26881541 )
2015
20
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. ( 26870618 )
2015
21
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. ( 25343957 )
2015
22
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25491280 )
2015
23
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. ( 26017341 )
2015
24
Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. ( 24991718 )
2015
25
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
26
Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1. ( 25012564 )
2014
27
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
28
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. ( 25180155 )
2014
29
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
30
A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. ( 23432689 )
2013
31
Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. ( 23904814 )
2013
32
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. ( 23222956 )
2013
33
Atypical chronic myeloid leukemia harboring NUP98-HOXA9. ( 23754767 )
2013
34
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia. ( 23264127 )
2013
35
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. ( 22289493 )
2012
36
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. ( 19168282 )
2009
37
JAK2 mutation and atypical chronic myeloid leukemia. ( 19427035 )
2009
38
The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. ( 19500135 )
2009
39
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ( 18555525 )
2008
40
A case of leukemic pleural infiltration in atypical chronic myeloid leukemia. ( 17043433 )
2006
41
Two clonal occurrences of tetrasomy 21 in an atypical chronic myeloid leukemia with wild-type RUNX1 alleles. Additional support for a gene dosage effect of chromosome 21 or RUNX1 in leukemia. ( 15339695 )
2004
42
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. ( 15034867 )
2004
43
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. ( 14504072 )
2003
44
Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. ( 12463598 )
2002
45
A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature. ( 9401502 )
1997
46
Atypical chronic myeloid leukemias. ( 9404484 )
1997
47
[Atypical chronic myeloid leukemia with polymorphism of the BCR gene]. ( 1687492 )
1991

Variations for Atypical Chronic Myeloid Leukemia

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

GO Terms for Atypical Chronic Myeloid Leukemia

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.83 ABL1 FGFR1 JAK2 PDGFRA
2 protein phosphorylation GO:0006468 9.8 ABL1 FGFR1 JAK2 PDGFRA
3 MAPK cascade GO:0000165 9.75 FGFR1 JAK2 PDGFRA
4 regulation of cell proliferation GO:0042127 9.72 ABL1 FGFR1 JAK2
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 ABL1 FGFR1 PDGFRA
6 cell migration GO:0016477 9.69 FGFR1 JAK2 PDGFRA
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.63 ABL1 JAK2 PDGFRA
8 peptidyl-tyrosine autophosphorylation GO:0038083 9.61 ABL1 JAK2
9 regulation of cell adhesion GO:0030155 9.61 ABL1 JAK2
10 thymus development GO:0048538 9.6 ABL1 ASXL1
11 regulation of cell differentiation GO:0045595 9.59 FGFR1 RUNX1
12 phosphatidylinositol-mediated signaling GO:0048015 9.58 FGFR1 PDGFRA
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.58 ABL1 JAK2 PDGFRA
14 skeletal system morphogenesis GO:0048705 9.57 FGFR1 PDGFRA
15 chondrocyte differentiation GO:0002062 9.56 FGFR1 RUNX1
16 regulation of actin cytoskeleton reorganization GO:2000249 9.48 ABL1 PDGFRA
17 protein autophosphorylation GO:0046777 9.46 ABL1 FGFR1 JAK2 PDGFRA
18 negative regulation of cell-cell adhesion GO:0022408 9.43 ABL1 JAK2
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 FGFR1 JAK2 PDGFRA
20 regulation of myeloid cell differentiation GO:0045637 9.37 CSF3R RUNX1
21 positive regulation of phospholipase C activity GO:0010863 9.32 FGFR1 PDGFRA
22 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ABL1 FGFR1 JAK2 PDGFRA
23 platelet-derived growth factor receptor signaling pathway GO:0048008 8.8 ABL1 JAK2 PDGFRA

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.77 ABL1 FGFR1 JAK2 PDGFRA RUNX1
2 kinase activity GO:0016301 9.62 ABL1 FGFR1 JAK2 PDGFRA
3 protein kinase activity GO:0004672 9.46 ABL1 FGFR1 JAK2 PDGFRA
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR1 PDGFRA
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.4 ABL1 JAK2
6 SH2 domain binding GO:0042169 9.26 ABL1 JAK2
7 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 FGFR1 JAK2 PDGFRA
8 protein tyrosine kinase activity GO:0004713 8.92 ABL1 FGFR1 JAK2 PDGFRA

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....